Drug Therapy

Sipuleucel-T (Provenge), an autologous cellular immunotherapy for metastatic, hormone-resistant prostate cancer, demonstrated few adverse events compared with controls in analysis of randomized clinical trials presented at the AUA annual meeting in San Francisco.

Prostate cancer patients on leuprolide (Lupron Depot) who were offered to continue on degarelix (Firmagon) after 1 year of treatment reduced PSA recurrence, according to results of a phase III extension study presented at the AUA annual meeting in San Francisco.

Urologists work with their patients to find out why they're not taking their meds.

Sexual side effects resulted in more withdrawals from dutaseride therapy compared to finasteride.

Gonadotropin-releasing hormone (GnRH) agonists have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several FDA studies.

This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes U.S. phase II bladder cancer trials that are currently recruiting participants. This list is current as of April 7, 2010.

Selenium and vitamin are E not promising, but both the Prostate Cancer Prevention Trial and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial showed a 20% to 25% reduction in the incidence of prostate cancer from two different 5-alpha-reductase inhibitors, finasteride (Proscar) and dutasteride (Avodart).

The first-ever presentation of phase III data from the investigational taxane cabazitaxel showed a 30% improvement in survival in men with metastatic castration-resistant prostate cancer.

Botulinum toxin A (Botox, Dysport) appears to be beneficial for the treatment of patients with idiopathic overactive bladder that is not adequately managed by anticholinergic drug therapy, according to a double-blind, placebo-controlled study presented at the European Association of Urology annual congress in Barcelona, Spain.

The experimental drug MDV3100 shows promise for the treatment of men with castration-resistant prostate cancer, researchers from Memorial Sloan-Kettering Cancer Center, New York, reported in a recently published study.

A retrospective, exploratory analysis of prospective clinical trials showed treatment-related hypertension was associated with significantly greater progression-free survival and overall survival in patients with metastatic renal cell carcinoma treated with sunitinib (Sutent), researchers reported at the 2010 Genitourinary Cancers Symposium in San Francisco.

Recently published study results indicate that dutasteride (Avodart) reduces the risk of prostate cancer in high-risk men, but publication of the results and an accompanying editorial may reignite the debate over whether 5-alpha-reductase inhibitors promote the growth of high-grade tumors.

The oral angiogenesis inhibitor pazopanib (Votrient) more than doubled progression-free survival versus placebo in a randomized, phase III trial of patients with advanced renal cell carcinoma.

This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes phase II, III, and IV erectile dysfunction trials that are currently recruiting participants. This list is current as of March 17, 2010.

The FDA has approved the first generic version of tamsulosin hydrochloride capsules, 0.4 mg, to treat BPH.

The FDA has approved triptorelin pamoate (Trelstar) 22.5 mg, a new twice-yearly formulation for the palliative treatment of advanced prostate cancer.

Sipuleucel-T (Provenge) extends overall survival in men with metastatic, castrate-resistant prostate cancer, investigators in Dendreon Corp.?s phase III IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study recently announced at the 2010 Genitourinary Cancers Symposium in San Francisco.

Results from a phase III trial have shown that cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel (Taxotere)-based chemotherapy.

Mission Pharmacal Co. recently introduced a potassium citrate (Urocit-K 15 mEq) extended-release tablet for the prevention of kidney stone recurrence.

The prostate cancer drug abiraterone shows encouraging results in men who have exhausted standard treatment options, according to recent clinical trial results.

The Institute for Safe Medication Practices has reported medication errors due to name confusion between dexlansoprazole (Kapidex) and bicalutamide (Casodex).

Denosumab appears to delay skeletal-related events in patients suffering from metastatic prostate cancer, according to results of a phase III, head-to-head trial evaluating denosumab versus zoledronic acid (Zometa).

Men on statin therapy before radical prostatectomy had a 30% lower risk of cancer recurrence.

This list of U.S.-based clinical trials is derived from the National Institute of Health's database and includes phase III advanced prostate cancer trials that are currently recruiting participants as of Jan. 22, 2010.

An investigational treatment for premature ejaculation, PSD502, appears to delay ejaculation up to five times longer than placebo, according to a study presented at the 2009 Sexual Medicine Society of North America annual meeting in San Diego.

Robert J. Evans III, MD, has joined the department of urology at Wake Forest University Baptist Medical Center, Winston-Salem, NC.

Submucosal injection of the steroid triamcinolone (Kenalog) is a safe, effective alternative to fulguration or laser ablation for treating Hunner's ulcers in interstitial cystitis patients.

Long-term, reliable use of antimuscarinics in patients with overactive bladder is significantly lower than past clinical trials have suggested.

In a study of men with metastatic castration-resistant prostate cancer, the novel investigational agent OGX-011 showed a trend for overall survival while only modestly affecting PSA levels.

A recent study designed to determine the efficacy of intravesical botulinum toxin in patients with neurogenic detrusor overactivity and urinary incontinence secondary to spinal cord injury or multiple sclerosis showed positive results.